28 Oct, 2020
BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related
25 Sep, 2020
Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials Boston, MA/Copenhagen, Denmark, September 25, 2020 –  Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and
19 May, 2020
Appoints Amit Munshi as Chair, deeply experienced industry executive, CEO of Arena Pharmaceuticals Succeeds Magnus Persson, who oversaw period of rapid growth and success for Galecto Appoints David Shapiro MD, former CMO of Intercept Pharmaceuticals, to Board of Directors Boston, MA/Copenhagen,
27 Apr, 2020
Copenhagen, Denmark, April 27, 2020  –  Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Jonathan Freve, CPA, as its Chief Financial Officer (CFO).